

Tore K. Kvien

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6434838/publications.pdf>

Version: 2024-02-01

101
papers

20,819
citations

100601

38
h-index

43601

95
g-index

102
all docs

102
docs citations

102
times ranked

18280
citing authors

#	ARTICLE	IF	CITATIONS
1	Psoriatic arthritis, axial spondyloarthritis and rheumatoid arthritis in Norway: nationwide prevalence and use of biologic agents. <i>Scandinavian Journal of Rheumatology</i> , 2023, 52, 42-50.	0.6	11
2	Secukinumab and Sustained Reduction in Fatigue in Patients With Ankylosing Spondylitis: <sc>Long-Term</sc> Results of Two Phase <sc>III</sc> Randomized Controlled Trials. <i>Arthritis Care and Research</i> , 2022, 74, 759-767.	1.5	10
3	Two-year reduction of dual-energy CT urate depositions during a treat-to-target strategy in gout in the NOR-Gout longitudinal study. <i>Rheumatology</i> , 2022, 61, S181-S185.	0.9	17
4	Associations between joint pathologies and central sensitization in persons with hand osteoarthritis: results from the Nor-Hand study. <i>Rheumatology</i> , 2022, 61, 2316-2324.	0.9	2
5	Real-World Six- and Twelve-Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries. <i>Arthritis Care and Research</i> , 2022, 74, 1205-1218.	1.5	20
6	Associations of pain sensitisation with tender and painful joint counts in people with hand osteoarthritis: results from the Nor-Hand study. <i>RMD Open</i> , 2022, 8, e001774.	1.8	1
7	Inflammation and biologic therapy in patients with rheumatoid arthritis achieving versus not achieving ACR/EULAR Boolean remission in a treat-to-target study. <i>RMD Open</i> , 2022, 8, e002013.	1.8	4
8	The cost savings of biosimilars can help increase patient access and lift the financial burden of health care systems. <i>Seminars in Arthritis and Rheumatism</i> , 2022, 52, 151939.	1.6	41
9	Associations of Body Mass Index With Pain and the Mediating Role of Inflammatory Biomarkers in People With Hand Osteoarthritis. <i>Arthritis and Rheumatology</i> , 2022, 74, 810-817.	2.9	15
10	Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study. <i>Lancet Rheumatology</i> , The, 2022, 4, e177-e187.	2.2	122
11	One- and 2-year flare rates after treat-to-target and tight-control therapy of gout: results from the NOR-Gout study. <i>Arthritis Research and Therapy</i> , 2022, 24, 88.	1.6	12
12	Patient Experienced Symptom State in rheumatoid arthritis: sensitivity to change in disease activity and impact. <i>Rheumatology</i> , 2022, 62, 98-107.	0.9	1
13	Immunogenicity and Safety of Standard and <sc>Third-Dose SARS</sc> â€“ <sc>CoV</sc> â€“2 Vaccination in Patients Receiving Immunosuppressive Therapy. <i>Arthritis and Rheumatology</i> , 2022, 74, 1321-1332.	2.9	31
14	EULAR 75-year anniversary: commentaries on key ARD papers from 1947. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 751-752.	0.5	4
15	Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the â€“JAK-potâ€“™ collaboration. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1358-1366.	0.5	48
16	Get a Grip on Factors Related to Grip Strength in Persons With Hand Osteoarthritis: Results From an Observational Cohort Study. <i>Arthritis Care and Research</i> , 2021, 73, 794-800.	1.5	14
17	Validity and reliability of the EULAR instrument RAID.7 as a tool to assess individual domains of impact of disease in rheumatoid arthritis: a cross-sectional study of 671 patients. <i>RMD Open</i> , 2021, 7, e001539.	1.8	10
18	Value of MRI and ultrasound for prediction of therapeutic response and erosive progression in patients with early rheumatoid arthritis managed by an aggressive treat-to-target strategy. <i>RMD Open</i> , 2021, 7, e001525.	1.8	16

#	ARTICLE	IF	CITATIONS
19	12-month results from the real-life observational treat-to-target and tight-control therapy NOR-Gout study: achievements of the urate target levels and predictors of obtaining this target. RMD Open, 2021, 7, e001628.	1.8	16
20	Serum golimumab concentration and anti-drug antibodies are associated with treatment response and drug survival in patients with inflammatory joint diseases: data from the NOR-DMARD study. Scandinavian Journal of Rheumatology, 2021, 50, 445-454.	0.6	8
21	Rheumatoid factor and falsely elevated results in commercial immunoassays: data from an early arthritis cohort. Rheumatology International, 2021, 41, 1657-1665.	1.5	15
22	Joint tenderness and ultrasound inflammation in DMARD-naïve patients with early rheumatoid arthritis. Annals of the Rheumatic Diseases, 2021, 80, 1493-1494.	0.5	2
23	Study protocol for the follow-up examination of the Nor-Hand study: A hospital-based observational cohort study exploring pain and biomarkers in people with hand osteoarthritis. Osteoarthritis and Cartilage Open, 2021, 3, 100198.	0.9	2
24	<i>Rheumatology and Autoimmunity</i>â€”A new major development in Chinese rheumatology. Greetings from Norway!. Rheumatology & Autoimmunity, 2021, 1, 6-7.	0.3	0
25	Retention and response rates in 14 261 PsA patients starting TNF inhibitor treatmentâ€”results from 12 countries in EuroSpA. Rheumatology, 2020, 59, 1640-1650.	0.9	18
26	Associations Between Radiographic and Ultrasoundâ€”Detected Features in Hand Osteoarthritis and Local Pressure Pain Thresholds. Arthritis and Rheumatology, 2020, 72, 966-971.	2.9	11
27	What Next after Biologic Therapy Fails in Rheumatoid Arthritis?. New England Journal of Medicine, 2020, 383, 1588-1589.	13.9	4
28	Considerations for improving quality of care of patients with rheumatoid arthritis and associated comorbidities. RMD Open, 2020, 6, e001211.	1.8	17
29	Ultrasound shows rapid reduction of crystal depositions during a treat-to-target approach in gout patients: 12-month results from the NOR-Gout study. Annals of the Rheumatic Diseases, 2020, 79, 1500-1505.	0.5	33
30	Reply. Arthritis and Rheumatology, 2020, 72, 1407-1408.	2.9	0
31	Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration. RMD Open, 2020, 6, e001280.	1.8	33
32	Impact of discordance between patientâ€™s and evaluatorâ€™s global assessment on treatment outcomes in 14 868 patients with spondyloarthritis. Rheumatology, 2020, 59, 2455-2461.	0.9	7
33	Conventional versus ultrasound treat to target: no difference in magnetic resonance imaging inflammation or joint damage over 2 years in early rheumatoid arthritis. Rheumatology, 2020, 59, 2550-2555.	0.9	14
34	An Opportunity Missed: Biosimilars in the United States. Arthritis and Rheumatology, 2020, 72, 1046-1048.	2.9	5
35	Psychometric performance of the PANcreatic CANcer disease impact (PACADI) score. Pancreatology, 2019, 19, 971-978.	0.5	7
36	Swollen, but not tender joints, are independently associated with ultrasound synovitis: results from a longitudinal observational study of patients with established rheumatoid arthritis. Annals of the Rheumatic Diseases, 2019, 78, 1179-1185.	0.5	38

#	ARTICLE	IF	CITATIONS
37	Peripheral and Central Sensitization of Pain in Individuals With Hand Osteoarthritis and Associations With Self-Reported Pain Severity. <i>Arthritis and Rheumatology</i> , 2019, 71, 1070-1077.	2.9	29
38	Associations between certolizumab pegol serum levels, anti-drug antibodies and treatment response in patients with inflammatory joint diseases: data from the NOR-DMARD study. <i>Arthritis Research and Therapy</i> , 2019, 21, 256.	1.6	18
39	Phrasing of the patient global assessment in the rheumatoid arthritis ACR/EULAR remission criteria: an analysis of 967 patients from two databases of early and established rheumatoid arthritis patients. <i>Clinical Rheumatology</i> , 2018, 37, 1503-1510.	1.0	13
40	The confidence of rheumatologists about switching to biosimilars for their patients. <i>Joint Bone Spine</i> , 2018, 85, 507-509.	0.8	14
41	Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 3-17.	0.5	484
42	Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 165-174.	0.5	173
43	Biological treatment in ankylosing spondylitis in the Nordic countries during 2010–2016: a collaboration between five biological registries. <i>Scandinavian Journal of Rheumatology</i> , 2018, 47, 465-474.	0.6	22
44	Predictors of sustained remission in patients with early rheumatoid arthritis treated according to an aggressive treat-to-target protocol. <i>Rheumatology</i> , 2018, 57, 2022-2031.	0.9	19
45	New-generation JAK inhibitors: how selective can they be?. <i>Lancet, The</i> , 2018, 391, 2477-2478.	6.3	18
46	Frequency of temporomandibular joint osteoarthritis and related symptoms in a hand osteoarthritis cohort. <i>Osteoarthritis and Cartilage</i> , 2017, 25, 654-657.	0.6	37
47	2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 978-991.	0.5	1,220
48	Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. <i>Lancet, The</i> , 2017, 389, 2304-2316.	6.3	666
49	Drivers of patient global assessment in patients with rheumatoid arthritis who are close to remission: an analysis of 1588 patients. <i>Rheumatology</i> , 2017, 56, 1573-1578.	0.9	71
50	A hospital-based observational cohort study exploring pain and biomarkers in patients with hand osteoarthritis in Norway: The Nor-Hand protocol. <i>BMJ Open</i> , 2017, 7, e016938.	0.8	19
51	Efficacy of infliximab biosimilars in patients with Crohn's disease – Authors' reply. <i>Lancet, The</i> , 2017, 390, 2436.	6.3	1
52	Diagnostic spectrum and 2-year outcome in a cohort of patients with very early arthritis. <i>RMD Open</i> , 2017, 3, e000573.	1.8	6
53	Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: a EULAR initiative. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 965-973.	0.5	179
54	Synovitis and radiographic progression in non-erosive and erosive hand osteoarthritis: is erosive hand osteoarthritis a separate inflammatory phenotype?. <i>Osteoarthritis and Cartilage</i> , 2016, 24, 647-654.	0.6	60

#	ARTICLE	IF	CITATIONS
55	EXXELERATE: a negative trial with importance for clinical practice. <i>Lancet, The</i> , 2016, 388, 2718-2719.	6.3	1
56	Ultrasound in management of rheumatoid arthritis: ARCTIC randomised controlled strategy trial. <i>BMJ, The</i> , 2016, 354, i4205.	3.0	200
57	Predictive Value of Arterial Stiffness and Subclinical Carotid Atherosclerosis for Cardiovascular Disease in Patients with Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2016, 43, 1622-1630.	1.0	49
58	Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration. <i>Arthritis Research and Therapy</i> , 2016, 18, 50.	1.6	37
59	Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 3-15.	0.5	1,114
60	Effectiveness of an Integrated Multidisciplinary Osteoarthritis Outpatient Program versus Outpatient Clinic as Usual: A Randomized Controlled Trial. <i>Journal of Rheumatology</i> , 2016, 43, 411-418.	1.0	17
61	Less educated and older patients have reduced access to biologic DMARDs even in a country with highly developed social welfare (Norway): results from Norwegian cohort study NOR-DMARD. <i>Rheumatology</i> , 2016, 55, 1217-1224.	0.9	31
62	Increasing synovitis and bone marrow lesions are associated with incident joint tenderness in hand osteoarthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 702-708.	0.5	40
63	Rosuvastatin improves endothelial function in patients with inflammatory joint diseases, longitudinal associations with atherosclerosis and arteriosclerosis: results from the RORA-AS statin intervention study. <i>Arthritis Research and Therapy</i> , 2015, 17, 279.	1.6	29
64	Circulating levels of inflammatory cytokines and cytokine receptors in patients with ankylosing spondylitis: a cross-sectional comparative study. <i>Scandinavian Journal of Rheumatology</i> , 2015, 44, 118-124.	0.6	54
65	Disease Activity in Ankylosing Spondylitis and Associations to Markers of Vascular Pathology and Traditional Cardiovascular Disease Risk Factors: A Cross-sectional Study. <i>Journal of Rheumatology</i> , 2015, 42, 645-653.	1.0	33
66	Cost-effectiveness of TNF inhibitors vs synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a Markov model study based on two longitudinal observational studies. <i>Rheumatology</i> , 2015, 54, 1226-1235.	0.9	24
67	Do COX-2 inhibitors provide additional pain relief and anti-inflammatory effects in patients with rheumatoid arthritis who are on biological disease-modifying anti-rheumatic drugs and/or corticosteroids? Post-hoc analyses from a randomized clinical trial with etoricoxib. <i>BMC Musculoskeletal Disorders</i> , 2015, 16, 26.	0.8	11
68	Body mass index and progressive hand osteoarthritis: data from the Oslo hand osteoarthritis cohort. <i>Scandinavian Journal of Rheumatology</i> , 2015, 44, 331-336.	0.6	19
69	Time trends in disease activity, response and remission rates in rheumatoid arthritis during the past decade: results from the NOR-DMARD study 2000-2010. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 381-388.	0.5	142
70	SAT0119-Asymptomatic Carotid Plaques in RA Patients is Associated with Increased HDL Function. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 633.3-633.	0.5	0
71	First-time prescriptions of biological disease-modifying antirheumatic drugs in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis 2002-2011: data from the NOR-DMARD register. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1905-1906.	0.5	16
72	Inequities in access to biologic and synthetic DMARDs across 46 European countries. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 198-206.	0.5	289

#	ARTICLE	IF	CITATIONS
73	A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1012-1019.	0.5	314
74	AB0795 Cardiovascular Preventive Medication and Treatment Targets in Patients with Osteoarthritis: Results from the Must-Heart Study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1067.1-1067.	0.5	0
75	Cross-sectional and longitudinal associations between radiographic features and measures of pain and physical function in hand osteoarthritis. <i>Osteoarthritis and Cartilage</i> , 2013, 21, 1191-1198.	0.6	67
76	Treatment to lipid targets in patients with inflammatory joint diseases in a preventive cardio-rheuma clinic. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1968-1974.	0.5	57
77	Carotid artery plaques are associated with coronary atherosclerosis in patients with inflammatory joint diseases independent of several cardiovascular risk calculators. <i>European Heart Journal</i> , 2013, 34, P2485-P2485.	1.0	0
78	Remission and radiographic outcome in rheumatoid arthritis: application of the 2011 ACR/EULAR remission criteria in an observational cohort. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 681-686.	0.5	150
79	The Impact of Coping Strategies on Mental and Physical Well-Being in Patients with Rheumatoid Arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2012, 41, 545-555.	1.6	58
80	Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 47-53.	0.5	589
81	American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 404-413.	0.5	657
82	American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. <i>Arthritis and Rheumatism</i> , 2011, 63, 573-586.	6.7	864
83	Prevalence, incidence and progression of hand osteoarthritis in the general population: the Framingham Osteoarthritis Study. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1581-1586.	0.5	371
84	Performance of the Rheumatoid Arthritis Impact of Disease (RAID) score in relation to other patient-reported outcomes in a register of patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1080-1082.	0.5	39
85	Should Anti-citrullinated Protein Antibody and Rheumatoid Factor Status Be Reassessed During the First Year of Followup in Recent-Onset Arthritis? A Longitudinal Study. <i>Journal of Rheumatology</i> , 2011, 38, 2336-2341.	1.0	24
86	Sleep problems are of higher priority for improvement for patients with ankylosing spondylitis than for patients with other inflammatory arthropathies. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 872-873.	0.5	30
87	MRI in early rheumatoid arthritis: synovitis and bone marrow oedema are independent predictors of subsequent radiographic progression. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 428-433.	0.5	124
88	2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. <i>Arthritis and Rheumatism</i> , 2010, 62, 2569-2581.	6.7	6,781
89	EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatology. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1596-1602.	0.5	87
90	2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1580-1588.	0.5	2,994

#	ARTICLE	IF	CITATIONS
91	Health status and perception of pain: a comparative study between female patients with hand osteoarthritis and rheumatoid arthritis. <i>Scandinavian Journal of Rheumatology</i> , 2009, 38, 342-348.	0.6	38
92	Minimal clinically important improvement/difference (MCII/MCID) and patient acceptable symptom state (PASS): what do these concepts mean?. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, iii40-iii41.	0.5	200
93	Measuring disability and quality of life in established rheumatoid arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2007, 21, 827-840.	1.4	79
94	Epidemiological Aspects of Rheumatoid Arthritis: The Sex Ratio. <i>Annals of the New York Academy of Sciences</i> , 2006, 1069, 212-222.	1.8	248
95	Performance of the Norwegian version of AUSCAN – a disease-specific measure of hand osteoarthritis. <i>Osteoarthritis and Cartilage</i> , 2005, 13, 561-567.	0.6	43
96	Vertebral Deformities in Rheumatoid Arthritis. <i>Archives of Internal Medicine</i> , 2004, 164, 420.	4.3	129
97	Preferences for improved health examined in 1,024 patients with rheumatoid arthritis: Pain has highest priority. <i>Arthritis and Rheumatism</i> , 2002, 47, 391-397.	6.7	231
98	Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis: Results from 394 patients in the Oslo County rheumatoid arthritis register. <i>Arthritis and Rheumatism</i> , 2000, 43, 522.	6.7	616
99	Reduced bone mineral density in male rheumatoid arthritis patients: Frequencies and associations with demographic and disease variables in ninety-four patients in the Oslo county rheumatoid arthritis register. <i>Arthritis and Rheumatism</i> , 2000, 43, 2776-2784.	6.7	101
100	The Prevalence and Severity of Rheumatoid Arthritis in Oslo. <i>Scandinavian Journal of Rheumatology</i> , 1997, 26, 412-418.	0.6	155
101	Juvenile Ankylosing Spondylitis and HLA B27 Homozygosity. <i>Scandinavian Journal of Rheumatology</i> , 1985, 14, 47-50.	0.6	9